OR WAIT 15 SECS
January 10, 2017
Takeda (Osaka, Japan) and ARIAD Pharmaceuticals, Inc. (Cambridge, MA) have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction is expected to close by the end of February 2017.
Takeda reports that the acquisition of ARIAD brings two innovative targeted therapies into its existing oncology portfolio: Brigatinib, for non-small cell lung cancer, and Iclusichronic, for chronic myeloid leukemia.
Takeda will leverage ARIAD’s R&D capabilities and platform, and largely absorb its R&D costs within Takeda's existing R&D budget.